Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic prostate cancer, is a lethal tumor that most commonly arises in late stages of prostate adenocarcinoma (PCA) with predilection to metastasize to visceral organs. In the current study, we explore for evidence that Aurora kinase A (AURKA) and N-myc (MYCN) gene abnormalities are harbingers of treatment-related NEPC (t-NEPC). We studied primary prostate tissue from 15 hormone naïve PCAs, 51 castration-resistant prostate cancers, and 15 metastatic tumors from 72 patients at different stages of disease progression to t-NEPC, some with multiple specimens. Histologic evaluation, immunohistochemistry, and fluorescence in situ hybridization were performed and correlated with clinical variables. AURKA amplification was identified in overall 65% of PCAs (hormone naïve and treated) from patients that developed t-NEPC and in 86% of metastases. Concurrent amplification of MYCN was present in 70% of primary PCAs, 69% of treated PCAs, and 83% of metastases. In contrast, in an unselected PCA cohort, AURKA and MYCN amplifications were identified in only 5% of 169 cases. When metastatic t-NEPC was compared to primary PCA from the same patients, there was 100% concordance of ERG rearrangement, 100% concordance of AURKA amplification, and 60% concordance of MYCN amplification. In tumors with mixed features, there was also 100% concordance of ERG rearrangement and (M.A.R.), Early Detection Research Network NCI U01 CA111275 ( J.M.M. and M.A.R.), and the Prostate Cancer Foundation (H.B. and M.A.R.). M.A.R. is a co-inventor of the patent on the detection of gene fusions in prostate cancer, filed by the University of Michigan and the Brigham and Women's Hospital. The diagnostic field of use for ETS gene fusions has been licensed to Hologic Gen-Probe. The authors declare that there are no relationships that could be construed as resulting in an actual, potential, or perceived conflict of interest with regard to the current
Introduction
The development of neuroendocrine prostate cancer (NEPC, also referred to as anaplastic prostate cancer) is thought to drive approximately 25% of the nearly 34,000 cases per year of lethal prostate cancer in the United States [1] . However, data from autopsy studies suggest that the incidence of NEPC may be significantly underestimated [2] . It is known that the amount of neuroendocrine differentiation increases with disease progression and correlates with patient exposure to long-term androgen deprivation therapy. Preclinical studies also support transformation of prostate adenocarcinoma (PCA) cells into neuroendocrine cells when depleted of androgen in vitro and in xenograft models [3] [4] [5] [6] [7] . Therefore, with the introduction of new highly potent androgen receptor (AR)-targeted therapies into the clinic, the incidence of treatment-related NEPC (t-NEPC) might escalate. Patients who develop t-NEPC have an aggressive clinical course and often develop visceral metastases, and most survive less than 1 year [8] . Because neuroendocrine cells do not express AR or secrete prostate-specific antigen (PSA), the PSA level tends to be low or does not elevate in proportion to clinical progression. Elevated serum markers of neuroendocrine differentiation, such as chromogranin A and neuron-specific enolase (NSE), may support the diagnosis.
The prostate cancer-specific ERG gene rearrangement occurs in approximately 50% of t-NEPC [9] [10] [11] and there is concordance of ERG status and other molecular abnormalities between PCA and t-NEPC foci of mixed tumors [11] ; these data strongly suggest that there is a similar cell of origin of PCA and t-NEPC. This also distinguishes t-NEPC from neuroendocrine tumors arising from other anatomic sites and suggests that molecular studies of PCA may provide insight into events that occur early before the development of t-NEPC.
We recently demonstrated that the cell cycle kinase, Aurora kinase A, and the transcription factor, N-myc, cooperate to induce neuroendocrine differentiation in prostate cancer [12] . Furthermore, treatment of NEPC models with an Aurora kinase inhibitor resulted in significant tumor shrinkage and reversal of the neuroendocrine phenotype, thereby providing rationale for clinical evaluation of an Aurora kinase inhibitor for patients with t-NEPC. In that study, we also showed that concurrent overexpression and amplification of the Aurora kinase A gene (AURKA) and N-myc gene (MYCN ) in metastatic t-NEPC was significantly higher (40%) when compared to an unselected cohort of localized PCA (5%). Interestingly, one of the patients who progressed from PCA to t-NEPC had amplification of AURKA and MYCN in his primary hormone naïve PCA, suggesting that these molecular events occur early in the disease [12] .
In the current study, we examined the histologic spectrum of t-NEPC and evaluated AURKA and MYCN amplifications in primary prostate tumors and metastases from 72 patients who developed lethal t-NEPC.
Materials and Methods

Case Selection
Pathology material from 72 patients who clinically developed NEPC was evaluated. Clinical parameters for the diagnosis of NEPC included rapid progression of the disease with visceral metastases in the setting of low (≤10 ng/ml) or modestly rising PSA and/or elevated neuroendocrine serum markers (chromogranin A > 5× upper limit of normal, NSE > 2× upper limit of normal). All patients received androgen deprivation therapy before disease progression toward NEPC. Cases were identified at different collaborating institutions under Institutional Review Board (IRB)-approved protocols for the purpose of this study. The clinical information collected for each patient included the age at diagnosis of PCA, clinical stage, type of primary and systemic therapy, interval of time between initial diagnosis and castration-resistant state, interval of time between castration-resistant prostate cancer (CRPC) and metastatic disease including sites of metastases, and death.
For comparison purposes, an unselected cohort of 169 patients with localized PCA who underwent radical prostatectomy (RP) at Weill Cornell Medical Center was used. In addition, two pathology specimens from patients with primary (de novo) mixed small cell carcinoma with prostatic adenocarcinoma were assessed, and six prostatectomy cases of hormone naïve, localized PCA with Paneth cell-like neuroendocrine change were included in the study as separate controls of low-grade neuroendocrine differentiation [13] .
A summary of clinical characteristics of patients included in the study is presented in Table 1 .
Pathologic Evaluation
Formalin-fixed paraffin-embedded tissue of the aforementioned cases was available. Regarding archival material from the 72 patients who clinically progressed to t-NEPC, different specimens were available corresponding to different stages of disease (see below). Hematoxylin and eosin (H&E)-stained slides from surgical resections and biopsies were reviewed by study pathologists (J.M.M., K.P., B.D.R., and M.A.R.). Pathologic evaluation included Gleason score of untreated tumors (prostate biopsy, transurethral resection, and/or prostatectomy specimens), histologic examination of metastases and treated prostate tumors, and pathologic tumor stage. Classification of the spectrum of neuroendocrine tumors, both primary and metastatic PCAs, was applied using the definitions used in lung classification [14, 15] . Briefly, tumors with neuroendocrine morphology were small cell carcinoma (pure or combined) and large cell neuroendocrine carcinoma, and non-small cell carcinomas were poorly differentiated adenocarcinomas of the prostate with or without neuroendocrine differentiation. Poorly differentiated adenocarcinomas were considered to have neuroendocrine differentiation when more than 30% of tumor cells were positive for synaptophysin or chromogranin A.
Archival tissue from the 72 patients who developed t-NEPC included 11 primary hormone naïve PCA cases only (matched treated PCA or metastasis unavailable), 1 case of hormone naïve PCA with available tissue of treated PCA and metastases, 3 cases of hormone naïve PCA and subsequent metastases after treatment (matched treated PCA unavailable), 49 treated PCA only (matched hormone naïve PCA or metastases unavailable), 1 treated PCA and subsequent metastases (matched hormone naïve PCA unavailable), and 7 cases of metastases only (matched hormone naïve or treated PCA unavailable) ( Table 1 and Figure W1A ). A total of 15 metastatic tumors from 12 patients were interrogated. Sites of metastases included retroperitoneum (n = 1), colon (n = 1), bladder (n = 3), brain (n = 2), pleura (n = 1), pelvic soft tissue (n = 2), liver (n = 1), and bone (n = 4). Some patients presented with synchronous metastases at other anatomic locations including peritoneum, lungs, and stomach.
Overall, the assessed pathology material of these patients, some with multiple specimens from different stages in progression toward t-NEPC, included 15 hormone naïve clinically localized PCAs and 66 treated tumors: 51 treated PCAs and 15 metastases, the latter being from 12 patients (see Figure W1A ).
A subset of 19 neuroendocrine tumors from non-prostate origin was also interrogated for AURKA and MYCN amplifications and included primary small cell carcinoma of lung (n = 12) and bladder (n = 2), metastatic small cell carcinoma of lung to cerebellum (n = 1), welldifferentiated neuroendocrine tumor ("typical carcinoid") of bowel (n = 1), metastatic well-differentiated neuroendocrine tumor ("typical carcinoid") of bowel to liver (n = 1) and lung (n = 1), and mammary ductal carcinoma in situ with neuroendocrine differentiation (n = 1).
Fluorescence In Situ Hybridization
To assess AURKA and MYCN amplifications and PTEN status, we used a locus-specific probe plus reference probe fluorescence in situ hybridization (FISH) assays as previously described [12, 16] . The reference probe was located at 10q25 (BAC RP11431P18), spanning a stable region of the chromosome. Amplification was defined as the presence of four or more copies on average for gene-specific (AURKA or MYCN) signals per nucleus compared to two reference signals. ERG rearrangement was assessed using dual-color break-apart interphase FISH assay as described previously [17, 18] . At least 50 nuclei were evaluated per tissue section using a fluorescence microscope (Olympus BX51; Olympus Optical, Tokyo, Japan).
Immunohistochemistry
Immunohistochemistry (IHC) stain was performed in a subset of 44 cases using antibodies for synaptophysin (Clone SP11 from Lab Vision/Thermo Fisher Scientific, Kalamazoo, MI) and chromogranin A (Clone LK2H10 from Biogenex, Fremont, CA), following vendors' specified optimal dilutions for IHC. In a subset of 15 cases (primary PCA of patients who developed t-NEPC), IHC for Aurora kinase A was performed (ab13824 from Abcam Inc, Cambridge, MA; 1:800 dilution).
Results
Clinical Characteristics of Patients Who Progressed to t-NEPC
Full clinical information was available in 43 of 72 patients and partial clinical information in the remaining 29 patients. The age at diagnosis of PCA ranged from 42 to 84 years (median = 65 years). Time interval to progression to CRPC ranged from 2 to 10 years (median = 4 years), time on androgen deprivation therapy ranged from 1 to 11 years (median = 4 years), and overall survival after clinical diagnosis of NEPC ranged from 8 to 14 months (median = 12 months).
Treatment modalities received since diagnosis of PCA encompassed one or more of the following: RP, radiation therapy (external beam radiation and brachytherapy), androgen deprivation therapy such as luteinizing hormone-releasing hormone analogs, luteinizing hormone-releasing hormone antagonists, and anti-androgens including MDV3100 and abiraterone, and chemotherapy protocols with carboplatin + paclitaxel, carboplatin + etoposide, docetaxel, irinotecan, docetaxel + radium-223 chloride.
Detailed treatment received including hormonal and chemotherapy in a subset of patients along with survival, pathology, and FISH data is presented in Table W1 .
The age at diagnosis of PCA in the unselected cohort of 169 patients used for comparison (RP only) ranged from 42 to 75 years (median = 62 years).
Histopathology
Microscopic evaluation of 51 treated PCA cases and 15 metastases demonstrated three major histologic groups: 1) pure neuroendocrine prostate carcinoma, which included small cell carcinoma (n = 18) and large cell neuroendocrine carcinoma (n = 1); 2) poorly differentiated adenocarcinoma with (n = 21) or without (n = 8) neuroendocrine differentiation; 3) mixed neuroendocrine carcinoma and adenocarcinoma (n = 18). Among the latter group of 18 cases with mixed morphology, the neuroendocrine carcinoma component included areas of small cell carcinoma (n = 15) and large cell neuroendocrine carcinoma (n = 3) ( Table 2 ). The spectrum of NEPC, primary and metastatic, is illustrated in Figure 1 .
The prostate specimens from two patients who presented with primary (de novo) NEPC corresponded to one case of mixed small Archival material studied from patients who developed t-NEPC (n = 72), 100%
Primary hormone naïve PCA only (n = 11), 15.3% Primary hormone naïve PCA, treated PCA, and subsequent metastases (n = 1), 1.4% Primary hormone naïve PCA and subsequent metastases (n = 3), 4.2% Gleason score of localized PCA: 3+3=6 to 5+5=10 Pathologic stage of localized PCA: pT2c N0 to pT3a N1 Treated PCA only (n = 49), 68.0% Treated PCA and subsequent metastases (n = 1), 1.4% Metastases only* (n = 7), 9.7% Age at diagnosis of PCA: 42 to 84 years (median = 65 years) Time interval to progression to CRPC: 2 to 10 years (median = 4 years) Overall survival after clinical diagnosis of NEPC: 8 to 14 months (median = 12 months) Treatments received as monotherapy or in combination: RP, radiation therapy, androgen deprivation therapy including MDV3100 or abiraterone, chemotherapy (carboplatin + taxol, carboplatin + etoposide, docetaxel, irinotecan, docetaxel + radium-223 chloride) (Table W1) Unselected cohort of patients with localized PCA who underwent RP (n = 169), 100% Age at diagnosis of PCA: 42 to 75 years (median = 62 years) Gleason score of localized PCA: 3+3=6 to 4+5=9 Pathologic stage of localized PCA: pT2a N0 to pT3b N0
Primary (de novo) NEPC (mixed small cell carcinoma and PCA) (n = 2), 100% Age at diagnosis of de novo NEPC: 65 and 67 years Pathologic stage (RP performed): pT3a N0 both cases
Localized PCA with Paneth cell-like neuroendocrine differentiation (n = 6), 100% Age at diagnosis of PCA: 54 to 74 years (median = 65 years) Gleason score of localized PCA: 3+3=6 to 4+5=9 Pathologic stage of localized PCA: pT2a N0 to pT3b N1 *Fifteen metastatic sites included retroperitoneum (one), colon (one), bladder (three), brain (two), pleura (one), pelvic soft tissue (two), liver (one), and bone (four).
cell carcinoma with areas of PCA Gleason score 5 + 4 = 9 (prostate needle biopsies) and one case of mixed large cell neuroendocrine carcinoma with areas of PCA with ductal features (transurethral resection of prostate). The Gleason scores of 15 hormone naïve PCAs (i.e., initial diagnosis of patients who later developed t-NEPC) ranged from 3 + 3 = 6 to 5 + 5 = 10, and their pathologic tumor stage ranged from pT2c N0 to pT3a N1. Areas of benign prostate tissue were also identified in these 15 specimens.
The Gleason scores of the unselected cohort of 169 cases of localized PCA ranged from 3 + 3 = 6 to 4 + 5 = 9, and their pathologic tumor stage ranged from pT2a N0 to pT3b N0. In addition, archival material from this control cohort also included 50 benign prostate tissue samples. Gleason scores of the six PCA cases with Paneth cell-like neuroendocrine differentiation ranged from 3 + 3 = 6 to 4 + 5 = 9 (Table 1) .
FISH and IHC Results
In the group of primary hormone naïve PCA cases from patients who clinically progressed to t-NEPC, AURKA amplification was identified in 10 of 15 (67%) cases, seven of which (70%) also had concurrent MYCN amplification. Protein overexpression of Aurora kinase A was confirmed by IHC in five of such seven cases. Aurora kinase A overexpression was seen as multifocal and scattered positive nuclei, as illustrated in Figure W2 . The presence of AURKA or MYCN amplification was not associated with neuroendocrine marker (synaptophysin and chromogranin A) expression in these primary PCA cases.
Among t-NEPC cases, AURKA amplification was identified in 29 of 46 (63%) treated PCAs and in 12 of 14 (86%) metastases that were assessable. Concurrent MYCN amplification was present in 20 of 29 treated tumors (69%) and in 10 of 12 metastases (83%) that were evaluable (see Figure W1B ). In only two of all 75 specimens assessable by FISH did MYCN gain occurred without concurrent AURKA amplification; both cases previously treated with hormonal therapy, one was obtained from prostate and the other from a bladder mass.
In contrast, AURKA amplifications were identified only in 5% (8 of 169 cases) of the unselected PCA cohort, with concurrent MYCN amplification identified in 7 of 169 of cases (not seen in absence of AURKA amplification). Particularly noteworthy is the fact that AURKA amplification was detected in all six cases of PCA with Paneth cell-like neuroendocrine differentiation, one of them with concurrent MYCN amplification ( Figure 2 ).
Of the two de novo NEPC cases, one showed AURKA amplification with concurrent MYCN polysomy, and the other one was negative for either amplification. The results of AURKA and MYCN amplifications by FISH are summarized in Table 3 .
AURKA and MYCN amplifications were detected in more than 95% of nuclei evaluated on each positive case. No AURKA or MYCN amplification was detected in benign prostate tissue (n = 50). In all cases of primary PCA, the presence of AURKA and MYCN amplifications was independent of other clinical prognostic features (Gleason grade, serum PSA, and stage) including neuroendocrine marker expression (chromogranin A and synaptophysin) by IHC.
In the five cases where metastatic t-NEPC was compared to primary PCA from the same patient, either hormone naïve or treated PCA, there was 100% concordance (five of five matching cases) of AURKA amplification. MYCN amplification was present in three of five cases (60% concordance), with metastatic t-NEPC demonstrating MYCN amplification at all times. Histologic and molecular findings of three of these cases are illustrated in Figure 3 . In prostate tumors with mixed features, there was 94% concordance in AURKA/ MYCN amplification between areas of neuroendocrine carcinoma and adenocarcinoma. An example of such combined histomorphology is highlighted in Figure 4 , with both areas showing AURKA and MYCN amplifications.
Overall, ERG rearrangement was observed in 29 of 69 (42%) assessable tumors (PCA and metastases) in the t-NEPC cohort, 10 through insertion and 19 through deletion. PTEN deletion was observed in 14 of 49 (29%) assessable cases, eight of which were also ERG rearranged. There was no association between AURKA/MYCN amplification and ERG rearrangement or PTEN deletion status. Among the five cases of metastatic t-NEPC with matching PCA (hormone naïve or treated), four were positive for ERG rearrangement in the PCA and corresponding metastases, and one was negative for such gene rearrangement in both sites. This 100% concordance of ERG rearrangement is compatible with a clonal origin of t-NEPC, identical to those findings observed in tumors with mixed features (Figure 4) .
In neuroendocrine tumors from non-prostate origin, AURKA amplification was detected in 10 of 11 (91%) assessable primary small cell carcinomas of lung including the metastasis to cerebellum and in one assessable primary small cell carcinoma of the bladder. MYCN amplification was detected in seven of these cases (64%), always in the presence of AURKA amplification. In contrast, AURKA/ MYCN amplifications were not seen in well-differentiated neuroendocrine tumor ("typical carcinoid") of bowel and metastases or in ductal carcinoma in situ with neuroendocrine differentiation.
Discussion
The findings of the current study suggest that a broader definition of NEPC is desirable to capture the wide spectrum of this disease. Although the occurrence of de novo NEPC is rare, the incidence of NEPC that secondarily arises with disease progression and after therapy appears common and is associated with poor clinical outcome [19] [20] [21] [22] [23] [24] [25] . Given emerging preclinical and clinical evidence supporting promotion of neuroendocrine transformation by androgen deprivation therapies [3] [4] [5] [6] [7] 26, 27] , we propose that these secondary NEPC tumors should be termed t-NEPC. Widely under-recognized, especially as patients with advanced stage disease are rarely biopsied to make the diagnosis, progression toward an AR-negative neuroendocrine phenotype is one proposed mechanism by which tumors acquire resistance to hormonal therapies. Thus, the landscape of advanced prostate cancer is evolving as novel potent AR-targeted therapies enter widespread clinical use (e.g., abiraterone acetate, MDV3100, TAK700) and patients develop resistance, and the incidence of t-NEPC will presumably escalate. Alternative mechanisms of resistance also include up-regulation or continued activation of the AR [28] . Recognition of resistance associated with the development of an AR-negative t-NEPC versus an AR-activated CRPC is essential, as this affects how patients may respond to subsequent therapies; for instance, patients with t-NEPC would be less likely to respond to hormonal agents and may better respond to chemotherapy or enrollment in a clinical trial.
Although there are some limitations regarding clinical data presented in the current study, this retrospective cohort represents the largest tissue collection of t-NEPC reported to date. The main purpose of this study was to generate hypotheses regarding novel biomarkers and insight into the pathogenesis of t-NEPC. This work will be the basis for future clinical studies, including the prospective evaluation of AURKA and MYCN in primary tumors and metastases from patients with t-NEPC. If validated in prospective trials, these biomarkers would be useful for clinical decision making. For this purpose, defining the histomorphology and molecular characterization of t-NEPC become critical steps toward understanding the spectrum of disease, especially as efforts are made to incorporate the latest discoveries into the clinic, either as potential targets or in the form of significant biomarkers, both for diagnostic and prognostic uses. Planned clinical trials incorporating metastatic tumor biopsies for patients with CRPC including those patients with NEPC treated with an Aurora kinase inhibitor will be valuable for prospective correlation of pathologic findings and genomic sequencing results with clinical features and will help further define t-NEPC. Former studies have described the phenotypic features of metastatic hormone-refractory PCA to bone [29] and visceral sites [30, 31] , and of pure small cell carcinoma of prostate, which occurrence is rare (less than 1% of PCA cases) [32] . Here, we highlight that most treated prostate tumors and metastases from patients who clinically developed NEPC, including de novo NEPC cases, are part of a morphologic spectrum that encompasses pure neuroendocrine histology and mixed tumors with areas of poorly differentiated adenocarcinoma. Although the term anaplastic small cell carcinoma has also been used clinically to describe tumor progression in patients with CRPC [33, 34] , the histologic features of treated prostate tumors from patients who progress to NEPC, both primary and metastatic, are heterogeneous. The term t-NEPC may be a more useful descriptor for the clinical scenario of patients with CRPC with rapid disease progression (visceral and/or lytic bone metastases) and low serum PSA, especially in the setting of potent androgen deprivation therapy.
Some molecular characteristics of CRPC (e.g., ERG, PTEN status) have been described earlier [30, [35] [36] [37] [38] . In our series, ERG rearrangement was observed in 42% of cases, which is at similar frequency as reported in other cohorts. However, ERG rearrangement occurred more often through deletion (as opposed to translocation), a finding that has been previously associated with an aggressive behavior [37, 39] . These findings also support clonal origin of t-NEPC and acinar prostate cancer, previously demonstrated by concordance of ERG rearrangement in tumors with mixed features [9] [10] [11] and in primary PCA and metastatic NEPC [8] (Figure 4 ). This has important clinical implications, as it suggests that adenocarcinomas may harbor molecular lesions before the development of t-NEPC, which is relevant toward the development of novel biomarkers and identifying patients at high risk for progression.
We previously identified higher expression and amplification of AURKA and MYCN in NEPC in contrast to hormone naïve PCA [12] . In the current study, AURKA amplification was also detected in overall 65% primary PCA from patients that later developed t-NEPC, with concurrent MYCN amplification in a substantial proportion of cases. This is highly significant, especially when compared to 5% frequency of AURKA and MYCN amplifications observed in an unselected primary PCA population. Furthermore, these alterations were independent of Gleason score, PSA level, or pathologic tumor stage at initial diagnosis, suggesting that they add prognostic value. In the current study, we also did not observe any correlation with Gleason score. Importantly, AURKA and MYCN amplifications were also seen in low-grade Gleason 3 + 3 = 6 tumors, the type of tumors that might be considered for active surveillance. Because AURKA and MYCN alterations arise early, other genetic changes are clearly also important for disease progression. There was also high concordance of AURKA and MYCN amplifications (100% and 60%, respectively) when ensuing t-NEPC or later metastases were also interrogated ( Figure 3) ; this suggests that AURKA and MYCN alterations are acquired early and persist during disease progression. The importance is two-fold: AURKA is targetable (i.e., Aurora kinase A inhibitors), and AURKA and MYCN amplifications may represent new prognostic and predictive biomarkers because, as demonstrated in our current study, their presence identifies patients with PCA who are at risk of progressing to t-NEPC after androgen deprivation therapy. These patients may therefore benefit from early intervention with an Aurora kinase A inhibitor.
Paneth cell-like change in PCA has been suggested to represent a low-grade neuroendocrine differentiation with generally favorable prognosis [13] . Noteworthy, all six cases of PCA with these features harbored AURKA amplification. This particular histomorphology of PCA may be enriched for AURKA amplification, with resultant significant clinical implication (Figure 2 ). This might therefore suggest that these tumors may not be low grade. In the prior study by Tamas and Epstein [13] , patients with PCA with Paneth cell-like neuroendocrine differentiation including tumors with Gleason pattern 5 had no evidence of progression with mean and median follow-ups ranging from 42.5 to 60.5 months. These criteria were used to assign PCA with Paneth cell-like neuroendocrine differentiation to a category of favorable prognosis. Given the high association with AURKA amplification and the development of t-NEPC illustrated in our current study, future studies with longer follow-up and detailed AURKA and MYCN amplifications were also identified in small cell carcinomas of non-prostate origin but not in well-differentiated neuroendocrine tumors. This warrants further exploration for the role of AURKA and MYCN in small cell carcinomas of other primary sites. In addition, it demonstrates that both AURKA and MYCN amplifications may be good markers of neuroendocrine differentiation, but unlike the recurrent ETS rearrangements or SPOP mutations [40] they are not PCA specific.
Finally, this study also highlights the divide between the clinical presentation of NEPC and the pathologist's view of NEPC. Surgical pathologists only rarely encounter NEPC in their routine clinical practice due in part to the rare nature of de novo small cell prostate cancer, selection bias toward cases that are amenable to surgery and radiation, and the near universal absence of systematic biopsies for men with CRPC. More recently, clinical protocols are incorporating biopsies during the treatment course of CRPC. As exposed in this study and other recent studies that have evaluated metastatic samples, there is a wider range of morphology than normally encountered in hormone naïve prostate cancer. As a result, there is a significant gap in knowledge as to how treatment alters the course of many solid tumors but particularly prostate cancer, when hormonal or taxanebased therapy can be administered on the basis of clinical symptoms of bone pain, radiology images, or elevated PSA results without first obtaining a tissue diagnosis. We anticipate that given the more aggressive approach to obtaining biopsies on clinical trials for CRPC, we will need to more formally address the pathologic and molecular changes that occur as a result of targeted therapies. Therefore, we would advocate keeping a more encompassing broad view for the definition of NEPC until we better understand the biology and response to treatment through emerging clinical trials with mandatory tissue biopsies.
In summary, t-NEPC is a clinical entity that has an array of histologic features including pure neuroendocrine morphology (small cell carcinoma in most cases) and mixed tumors with poorly differentiated adenocarcinoma component. AURKA and MYCN amplifications occur early and are present in hormone naïve tumors from patients who ultimately progress to t-NEPC after androgen deprivation therapy ( Figure 5 ). Therefore, AURKA and MYCN amplifications may be prognostic and predictive biomarkers, as they are harbingers of tumors at risk of progressing to t-NEPC after hormonal therapy and may identify patients that could potentially benefit from Aurora kinase inhibitor therapy. 
